A new trading day began on Monday, with Standard BioTools Inc (NASDAQ: LAB) stock price up 17.14%% from the previous day of trading, before settling in for the closing price of $1.05. LAB’s price has ranged from $0.92 to $2.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 11.61% over the last five years. Meanwhile, its annual earnings per share averaged 55.47%. With a float of $365.93 million, this company’s outstanding shares have now reached $379.09 million.
The firm has a total of 818 workers. Let’s measure their productivity. In terms of profitability, gross margin is 47.04%, operating margin of -82.21%, and the pretax margin is -78.07%.
Standard BioTools Inc (LAB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 3.66%, while institutional ownership is 72.28%. The most recent insider transaction that took place on May 23 ’25, was worth 1,344. In this transaction Chief Financial Officer of this company sold 1,428 shares at a rate of $0.94, taking the stock ownership to the 930,286 shares. Before that another transaction happened on May 23 ’25, when Company’s SVP & Chief Business Officer sold 13,217 for $0.94, making the entire transaction worth $12,437. This insider now owns 843,076 shares in total.
Standard BioTools Inc (LAB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 55.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 66.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Here are Standard BioTools Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Analysing the last 5-days average volume posted by the [Standard BioTools Inc, LAB], we can find that recorded value of 5.19 million was better than the volume posted last year of 1.79 million. As of the previous 9 days, the stock’s Stochastic %D was 44.37%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 41.61%, which indicates a significant increase from 40.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.17% in the past 14 days, which was higher than the 81.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0979, while its 200-day Moving Average is $1.5178. Now, the first resistance to watch is $1.4800. This is followed by the second major resistance level at $1.7300. The third major resistance level sits at $1.8700. If the price goes on to break the first support level at $1.0900, it is likely to go to the next support level at $0.9500. Now, if the price goes above the second support level, the third support stands at $0.7000.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
With a market capitalization of 467.18 million, the company has a total of 379,822K Shares Outstanding. Currently, annual sales are 174,430 K while annual income is -138,890 K. The company’s previous quarter sales were 40,800 K while its latest quarter income was -26,030 K.
